Chimeric antigen receptor (CAR) T cell therapy achieves outstanding results in blood cancer treatment, however, lacks behind in solid cancers. Imbalanced CAR signaling may limit long-term T cell functionality: too weak activation leads to inactivity, while overly strong activation causes activation-induced T cell exhaustion. The CAR’s antigen-recognition domain is the initiator of T cell signaling. Artificial intelligence (AI) now enables targeted design of this domain with great potential for improvement. This project investigates the impact of AI-based modifications to the CAR antigen-recognition domain on CAR T cell function. The goal is to develop CAR variants that promote sustained T cell activity and thereby improve therapy against solid tumors.